Evidence-based guidelines: response to Professor Gordon Parker's critique

References

• Grol R. Improving the quality of medical care: building bridges among professional pride, payer profit, and patient satisfaction. Journal of the American Medical Association 2001; 286: 2578–2585
   Google Scholar
• Parker G. Evaluating treatment for the mood disorders: time for the evidence to get real. Australian and New Zealand Journal of Psychiatry 2004; 38: 408–414
   Google Scholar
• AGREE Collaboration. Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument 2001, Available at: http://www.agreecollaboration.org (Accessed October 2004.)
   Google Scholar
• National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. National Health and Medical Research Council, Canberra 1999
   Google Scholar
• Boyce P, Ellis P, Penrose-Wall J. Introduction to the Royal Australian and New Zealand College of Psychiatrists clinical practice guideline series. Australian and New Zealand Journal of Psychiatry 2003; 37: 637–640
   Google Scholar
• Whittington C J, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–1345
   Google Scholar
• Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ 1998; 316: 509–513
   Google Scholar
• Eisinger G, Geller G, Burke W, et al. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet 1999; 353: 919–920
   Google Scholar
• Burgers J S, Bailey J V, Klazinga N S, et al. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002; 25: 1933–1939
   Google Scholar
• Kendell R E. The major functional psychoses: are they independent entities or part of a continuum? Philosophical and conceptual issues underlying the debate. Concepts of mental disorder, A Kerr, H McClelland. Gaskell, London 1991
   Google Scholar
• Parker G. Classifying depression: should paradigms lost be regained?. American Journal of Psychiatry 2000; 157: 1195–1203
   Google Scholar
• Angst J, Merikangas K R. Multi-dimensional criteria for the diagnosis of depression. Journal of Affective Disorders 2001; 62: 7–15
   Google Scholar
• Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. American Journal of Psychiatry 2003; 160: 4–12
   Google Scholar
• Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. American Journal of Psychiatry 2002; 159: 1470–1479
   Google Scholar
• Parker G, Hadzi-Pavlovic D. Melancholia. A disorder of movement and mood, G Parker, D Hadzi-Pavlovic. Cambridge University Press, Melbourne 1996
   Google Scholar
• Kirsch I, Moore T J, Scoboria A, et al. The emperor's new drugs: an analysis of antidepressant medication data, submitted to the US Food and Drug Administration. Prevention and Treatment 2002; 5: 1–11
   Google Scholar
• Anonymous Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. American Journal of Psychiatry 2000; 157(Suppl.4)1–45
   Google Scholar
• Anderson I M, Nutt D J, Deakin J F.W. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2000; 14: 3–20
   Google Scholar
• RANZCP Clinical Practice Guidelines Team for Depression Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004; 38: 389–407
   Google Scholar
• Hall J C. The other side of statistical significance. A review of Type II errors in the Australian medical literature. Australian and New Zealand Journal of Medicine 1982; 12: 7–9
   Google Scholar
• Wampold B, Minami T, Baskin T, et al. Meta-(re) analysis of the effects of cognitive therapy versus ‘other therapies’ for depression. Journal of Affective Disorders 2002; 68: 159–165
   Google Scholar
• Gloaguen V, Cottraux J, Cucherat M, et al. A meta-analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders 1998; 49: 59–72
   Google Scholar
• Ellis P M. Comment in: Review: cognitive therapy may be no more effective than other bona fide psychological therapies for depression. Journal of Affective Disorders, B Wampold, T Minami, T Baskin, S Tierney, 2002; 68: 159–165, A meta-(re) analysis of the effects of cognitive therapy versus ‘other therapies’ for depression
   Google Scholar
• Elkin I, Shea T, Watkins J T, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Archives of General Psychiatry 1989; 46: 971–982
   Google Scholar
• Stewart J, Garfinkel R, Nunes E V, et al. Atypical features and treatment response in the National Institute of Mental Health treatment of depression collaborative research program. Journal of Clinical Psychopharmacology 1998; 18: 429–434
   Google Scholar
• Williams J W, Mulrow C D, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000; 132: 743–756
   Google Scholar
• Ballesteros J, Callado L F. Effectiveness of pindolol plus serotonin reuptake inhibitors in depression: a meta-analysis of early and late outcomes from randomized controlled trials. Journal of Affective Disorders 2004; 79: 137–147
   Google Scholar
• Sokolski K N, Conney J C, Brown B J, et al. Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Research 2004; 125: 81–86
   Google Scholar
• Brousse G, Schmitt A, Chereau I, et al. Interest of the use of pindolol in the treatment of depression: review. Encephale 2003; 29: 338–350
   Google Scholar
• Olver J S, Cryan J F, Burrows G D, et al. Pindolol augmentation of antidepressants: a review and rationale. Australian and New Zealand Journal of Psychiatry 2000; 34: 71–79
   Google Scholar
• Corya S A, Andersen S W, Detke H C, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76 week open-label study. Journal of Clinical Psychiatry 2003; 64: 1349–1356
   Google Scholar
• Shelton R C. The combination of olanzapine and fluoxetine in mood disorders. Expert Opinion on Pharmacotherapy 2003; 47: 1175–1183
   Google Scholar